N/A
N=93
Cala ONE Device for Essential Tremor
Essential Tremor
Bottom Line
View on ClinicalTrials.gov: NCT02629614 ↗Enrolled (actual)
93
Serious AEs
0.0%
Results posted
Jul 2023
Primary outcome: Primary: Change in TETRAS Spiral Rating After Stimulation — 2.95; 2.63; 2.41; 2.23 score on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Cala ONE Device (Device)
- Age
- Adult, Older Adult · 22+ yrs
- Sex
- All
- Sponsor
- Cala Health, Inc.
- Primary completion
- Nov 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in TETRAS Spiral Rating After Stimulation |
2.95; 2.63; 2.41; 2.23 | — |
| SECONDARY Change in TETRAS Spiral Rating During Stimulation |
2.95; 2.63; 2.58; 2.26 | — |
| SECONDARY Self-report Improvement |
35; 23 | — |
Summary
This study evaluates the safety and effectiveness of the Cala ONE device to aid in the symptomatic relief of hand tremors in adult essential tremor subjects. This study is a prospective, randomized, double-blinded, sham-controlled study.
Eligibility Criteria
Inclusion Criteria
- 22 years or older
- A diagnosis of essential tremor as confirmed from clinical history and examination by a movement disorder neurologist
- Signed informed consent
- At least one hand exhibiting kinetic tremor ≥ 2 as assessed by the TETRAS Archimedes spiral task completed during the baseline evaluation, as assessed by the Investigator in-person.
- Score of 3 or above in any one of the items of the Bain & Findley ADL Scale
Exclusion Criteria
- Implanted electrical medical device, such as a pacemaker, defibrillator, or deep brain stimulator
- Previous thalamotomy procedure, including Stereotactic Thalamotomy, Gamma Knife Radiosurgical Thalamotomy, and focused ultrasound, for the treatment of tremor
- Suspected or diagnosed epilepsy or other seizure disorder
- Pregnant
- Swollen, infected, inflamed areas, or skin eruptions, open wounds, or cancerous lesions of skin at stimulation site
- Peripheral neuropathy affecting the tested upper extremity
- Alcoholism (score of 4 or higher on DSM-5)
- Other possible causes of tremor, including Parkinson's disease, drug-induced, enhanced physiological tremor, dystonia
- Other neurodegenerative disease like Parkinson-plus syndromes suspected on neurological examination. These include: multisystem atrophy, progressive supranuclear palsy, dementia with Lewy bodies, and cortical basal ganglionic degeneration
- Changes in medication for tremor within 1 month prior to study enrollment
- Change in antidepressant medication within 3 months prior to study enrollment
- Botulinum Toxin injection for hand tremor within 6 months prior to study enrollment
- Current participation in any other interventional research study
- Previous participation in any other Cala Health interventional research study
- Alcohol or caffeine consumption within 12 hours of study enrollment
Subjects already taking medications for their essential tremor will remain on their medications during the study with no changes in medication type or dosage levels.
Data sourced from ClinicalTrials.gov (NCT02629614). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.